Hepatitis E vaccination campaign in Bentiu, South Sudan





Hepatitis E cases have been reported in Bentiu, South Sudan since 2014, however, the current surge in cases began in July 2021. Since then, 667 patients have been confirmed to have contracted hepatitis E, of whom 13 have tragically died. Worryingly, the outbreak is continuing to escalate in terms of transmission and severity. Since 2022, Médecins Sans Frontières (MSF) has witnessed on average one person with hepatitis E dying per week, indicating a concerningly high mortality rate.

 

In response to the current hepatitis E outbreak in Bentiu, MSF is supporting the South Sudan Ministry of Health (MoH) to implement a “ground-breaking” hepatitis E vaccination campaign, vaccinating approximately 24,500 people.

 

On Tuesday 22 March 2022, the MoH and MSF started the first round of the hepatitis E vaccinations, which concluded on the 30 March. Second and third doses will be rolled out over the coming months. This is the first time this vaccine is being used in a mass vaccination campaign and during an active outbreak of hepatitis E. It is hoped that it will help to reduce morbidity and mortality of people living in the camp, and serve as an example for other governments dealing with outbreaks of hepatitis E in their own contexts.

 

Read the full story https://msf.or.ke/en/magazine/south-sudan-msf-and-ministry-health-implement-hepatitis-e-vaccination-campaign-bentiu







More of this tag...

Vaccine

Cross-genus protection against rat hepatitis E virus elicited by hepatitis E vaccination in humans
Published by , Zihao Chen, Siddharth Sridhar
Hepatitis E (HE), caused by Paslahepevirus balayani (bHEV), is one of the leading causes of acute viral hepatitis worldwide. As a vaccine-preventable disease, HE has been effectively controlled through the use of the world's first HE vaccine

Vaccine

Results from a large effectiveness trial evaluating the protection of pregnant women by HEV vaccine in Bangladesh
Published by Susanne Dudman, Asma Aziz
We conducted a large phase 4, double-blind, cluster-randomised trial in 67 villages in Matlab, Bangladesh, and hereby share some of our results. Between 2017 and2021, 19 460 participants were randomised to receive HEV239, a recombinant hepatitis E vi






EVENTS

2025-01-18

International Joint Meeting on Viral Infections of the Liver and the Heart (2025)
Day two of this symposium will place a special emphasis on Hepatitis E — a virus that, despite being the most common cause of viral hepatitis, offers a valuable opportunity for further research and understanding. Venue: Cantinerie Berlin Gustav-Meyer-Allee 25 13355 Berlin, Germany. Organisers: Prof. Dr. Jens Kurreck, Dr. rer. nat. Daniel Todt, Prof. Dr. med. Heiner Wedemeyer, More information: Medizinische Hochschule Hannover : International DFG/DZIF Joint Meeting on Viral Infections of the Liver and the Heart (mhh.de)

GHEP offers free membership for your better connection with the hepatitis E community